Contra Costa County Header
File #: 25-622    Version: 1 Name:
Type: Consent Item Status: Agenda Ready
File created: 2/12/2025 In control: BOARD OF SUPERVISORS
On agenda: 2/25/2025 Final action:
Title: APPROVE and AUTHORIZE the Purchasing Agent, or designee, to execute on behalf of the Health Services Director, a purchase order amendment with Boston Scientific Corporation to increase the payment limit by $184,000 to an amount not to exceed $784,000 for the purchase of vascular, urology, endoscopy, and other supplies as needed for Contra Costa Regional Medical Center with no change in the term ending May 31, 2025. (100% Hospital Enterprise Fund I)
Date Ver.Action ByActionResultTallyAction DetailsMeeting DetailsVideo
No records to display.

To:                                          Board of Supervisors

From:                                          Anna Roth, Health Services Director

Report Title:                     Amendment to Purchase Order with Boston Scientific Corporation

Recommendation of the County Administrator Recommendation of Board Committee

 

RECOMMENDATIONS:

APPROVE and AUTHORIZE the Purchasing Agent, or designee, to execute, on behalf of the Health Services Director, an amendment to purchase order #28564 with Boston Scientific Corporation to increase the payment limit by $184,000 to a new payment limit of $784,000 for the purchase of vascular, urology, endoscopy, and other supplies as needed for Contra Costa Regional Medical Center (CCRMC) with no change to the original term of July 1, 2023 through May 31, 2025.

 

FISCAL IMPACT:

Approval of this action will result in additional expenditures of up to $184,000 and will be funded by Hospital Enterprise Fund I revenues.

 

BACKGROUND:

Boston Scientific Corporation is a global medical technology company that develops, manufactures, and markets innovative medical devices used in a wide range of specialties, including cardiology, endoscopy, urology, neuromodulation, and peripheral interventions. The company is known for its minimally invasive medical solutions, such as stents, catheters, pacemakers, defibrillators, and surgical tools, which help improve patient outcomes and reduce recovery times. Boston Scientific serves hospitals, healthcare providers, and patients worldwide, focusing on advancing medical technology to enhance patient care and treatment options.

 

Interventional Urology Products from Boston Scientific are designed for diagnosing and treating urological conditions with minimally invasive solutions. These include stents, laser systems, resectoscopes, and neuromodulation devices for conditions like benign prostatic hyperplasia (BPH), kidney stones, urinary incontinence, and bladder cancer. The products aim to reduce the need for surgery, improve outcomes, and shorten recovery times for patients.

 

There has been an increase in the procurement of sling mesh and the TRUEtome 44 Cannulating Sphincterotome. Sling mesh is a surgical implant used in urogynecological procedures, primarily for the treatment of stress urinary incontinence (SUI) in women. It is designed to provide urethral support and help prevent involuntary urine leakage. The TRUEtome 44 Cannulating Sphincterotome, is a specialized medical device used in endoscopic retrograde cholangiopancreatography (ERCP) procedures to facilitate selective cannulation and sphincterotomy.

 

On July 11, 2023 the Board of Supervisors approved agenda C.98 to execute a purchase order with Boston Scientific Corporation in the amount of $600,000 for the purchase of vascular, urology, endoscopy, and other supplies for CCRMC during the period of July 1, 2023 through May 31, 2025.

 

Boston Scientific Corporation is a member of the Vizient Group Purchasing Organization (GPO), which allows CCRMC to leverage pricing discounts and deliver high-quality, cost-effective healthcare solutions.

 

CONSEQUENCE OF NEGATIVE ACTION:

If this action is not approved, CCRMC will not be able to acquire the specialty supplies essential for performing critical surgeries, potentially compromising patient care and treatment outcomes.